Pooya Farhangnia

Mr. Pooya Farhangnia

orcid
Research Assistant

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2024 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
PFPooya Farhangnia
Pooya Farhangnia
HKHossein Khorramdelazad
Hossein Khorramdelazad
HNHamid Nickho
Hamid Nickho
ADAli-Akbar Delbandi
Ali-Akbar Delbandi
Pancreatic cancer is a major cause of cancer-related death, but despondently, the outlook and prognosis for this resistant type of tumor have remained grim for a long time. Currently, it is extremely challenging to prevent or detect it early enough for effective treatment because patients rarely exhibit symptoms and there are no reliable indicators for detection. Most patients have advanced or spreading cancer that is difficult to treat, and treatments like chemotherapy and radiotherapy can only slightly prolong their life by a few months. Immunotherapy has revolutionized the treatment of pancreatic cancer, yet its effectiveness is limited by the tumor's immunosuppressive and hard-to-reach microenvironment. First, this article explains the immunosuppressive microenvironment of pancreatic cancer and highlights a wide range of immunotherapy options, including therapies involving oncolytic viruses, modified T cells (T-cell receptor [TCR]-engineered and chimeric antigen receptor [CAR] T-cell therapy), CAR natural killer cell therapy, cytokine-induced killer cells, immune checkpoint inhibitors, immunomodulators, cancer vaccines, and strategies targeting myeloid cells in the context of contemporary knowledge and future trends. Lastly, it discusses the main challenges ahead of pancreatic cancer immunotherapy.

11 May 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
PFPooya Farhangnia
Pooya Farhangnia
SGShamim Mollazadeh Ghomi
Shamim Mollazadeh Ghomi
SMShabnam Mollazadehghomi
Shabnam Mollazadehghomi
HNHamid Nickho
Hamid Nickho
MAMahzad Akbarpour
Mahzad Akbarpour
ADAli-Akbar Delbandi
Ali-Akbar Delbandi
The signaling lymphocytic activation molecule (SLAM) family receptors were discovered in immune cells for the first time. The SLAM-family receptors are a significant player in cytotoxicity, humoral immune responses, autoimmune diseases, lymphocyte development, cell survival, and cell adhesion. There is growing evidence that SLAM-family receptors have been involved in cancer progression and heralded as a novel immune checkpoint on T cells. Previous studies have reported the role of SLAMs in tumor immunity in various cancers, including chronic lymphocytic leukemia, lymphoma, multiple myeloma, acute myeloid leukemia, hepatocellular carcinoma, head and neck squamous cell carcinoma, pancreas, lung, and melanoma. Evidence has deciphered that the SLAM-family receptors may be targeted for cancer immunotherapy. However, our understanding in this regard is not complete. This review will discuss the role of SLAM-family receptors in cancer immunotherapy. It will also provide an update on recent advances in SLAM-based targeted immunotherapies.

27 June 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
PFPooya Farhangnia
Pooya Farhangnia
SGShamim Mollazadeh Ghomi
Shamim Mollazadeh Ghomi
MAMahzad Akbarpour
Mahzad Akbarpour
ADAli-Akbar Delbandi
Ali-Akbar Delbandi
Antibody-based cancer immunotherapy has become a powerful asset in the arsenal against malignancies. In this regard, bispecific antibodies (BsAbs) are a ground-breaking novel approach in the therapy of cancers. Recently, BsAbs have represented a significant advancement in improving clinical outcomes. BsAbs are designed to target two different antigens specifically. Over a hundred various BsAb forms currently exist, and more are constantly being manufactured. An antagonistic regulator of T cell activation is cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or CD152, a second counter-receptor for the B7 family of co-stimulatory molecules was introduced in 1996 by Professor James P. Allison and colleagues. Contrary to the explosive success of dual immune checkpoint blockade for treating cancers, a major hurdle still yet persist is that immune-related adverse events (irAEs) observed by combining immune checkpoint inhibitors (ICIs) or monoclonal antibodies such as ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). A promising strategy to overcome this hurdle is using BsAbs. This article will summarize BsAbs targeting CTLA-4, their applications in cancer immunotherapy, and relevant clinical trial advances. We will also discuss the pre-clinical rationale for using these BsAbs, and provide the current landscape of the field.


1 December 2021 in Life Sciences
Verified
Journal Article
Closed access
SASara Adibfar
Sara Adibfar
MEMarischa Elveny
Marischa Elveny
HKHadisha Sh. Kashikova
Hadisha Sh. Kashikova
MMMaria Vladimirovna Mikhailova
Maria Vladimirovna Mikhailova
PFPooya Farhangnia
Pooya Farhangnia
FJFarhad Jadidi-Niaragh
Farhad Jadidi-Niaragh

2 May 2024 in Reproductive Health
Verified
Journal Article
Open access
PDF file
PFPooya Farhangnia
Pooya Farhangnia
MNMorvarid Noormohammadi
Morvarid Noormohammadi
ADAli-Akbar Delbandi
Ali-Akbar Delbandi
Vitamin D is a fat-soluble steroid hormone that was initially known only for regulating calcium and phosphorus levels and maintaining bone health. However, it was later discovered that many organs express vitamin D metabolizing enzymes and have a ligand for vitamin D, which regulates the expression of an extensive assortment of genes. As a result, vitamin D is indispensable for the proper function of organs, and its deficiency is believed to be a critical factor in symptoms and disorders such as cardiovascular diseases, autoimmune diseases, and cancers. The significance of vitamin D in reproductive tissues was recognized later, and studies have revealed its crucial role in male and female fertility, as well as proper reproductive function during pregnancy. Vitamin D deficiency has been identified as a risk factor for infertility, gonadal cancers, pregnancy complications, polycystic ovary syndrome, and endometriosis. However, data investigating the association between vitamin D levels and reproductive disorders, including endometriosis, have encountered inconsistencies. Therefore, the present study aims to review existing research on the effect of vitamin D on proper reproductive function, and the role of deficiency in reproductive diseases and specifically focuses on endometriosis.